Medicines access programs to cancer medicines in Australia and New Zealand: An exploratory study-Reference-Cited by-同舟云学术

Medicines access programs to cancer medicines in Australia and New Zealand: An exploratory study

Published:2018-03 Issue:3 Volume:122 Page:243-249
ISSN:0168-8510
Container-title:Health Policy
language:en
Short-container-title:Health Policy

Author:

Grover Piyush,Babar Zaheer-Ud-Din,Oehmen Raoul,Vitry Agnes

Publisher

Elsevier BV

Subject

Health Policy

Reference38 articles.

1. Affordable access to innovative cancer medicines − don't forget the prices;Ghinea;Medical Journal of Australia,2016

2. Differences in Australian and New Zealand medicines funding policies;Babar;Australian Prescriber,2014

3. International variability in the reimbursement of cancer drugs by publically funded drug programs;Cheema;Current Oncology,2012

4. The Senate Community Affairs References Committee. Availability of new, innovative and specialist cancer drugs in Australia. 2015; [Accessed 12 December 2015] http://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Community_Affairs/Cancer_Drugs.

5. Access to new cancer medicines in Australia: dispelling the myths and informing a public debate;Vitry;Journal of Pharmaceutical Policy and Practice,2016

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost and public reimbursement of cancer medicines in the UK and the Republic of Ireland;Irish Journal of Medical Science (1971 -);2022-04-21

2. Financing Strategies to Facilitate Access to High-Cost Anticancer Drugs: A Systematic Review of the Literature;International Journal of Health Policy and Management;2021-09-22

3. “There are ways … drug companies will get into DTC decisions”: How Australian drug and therapeutics committees address pharmaceutical industry influence;British Journal of Clinical Pharmacology;2020-11-26

4. Demonstrating the feasibility of collecting secondary, de‐identified data on Australian patients receiving treatment as part of a Medicine Access Programme;Internal Medicine Journal;2020-01

5. Access to High-Cost Medicines in Australia;Equitable Access to High-Cost Pharmaceuticals;2018